Paul Robbins
Vice President - Translational Sciences Allogene Therapeutics
Seminars
Thursday 5th February 2026
Roundtable Discussion: Designing Clinical Trials with MRD as a Patient Identification Tool to Transform Precision Oncology
11:55 am
- What are the biggest opportunities and limitations of leveraging MRD as a patient identification tool compared with its use for monitoring or as a trial endpoint?
- How are pharma and biotech teams approaching assay selection given variability in MRD sensitivity and methodologies?
- What practical challenges – regulatory, operational, or clinical – remain for embedding MRD-driven patient identification into trial design at scale?
